Integrins have a critical role in thrombosis and haemostasis 1 . Antagonists of the platelet integrin a IIb b 3 are potent anti-thrombotic drugs, but also have the life-threatening adverse effect of causing bleeding 2, 3 . It is therefore desirable to develop new antagonists that do not cause bleeding. Integrins transmit signals bidirectionally 4, 5 . Inside-out signalling activates integrins through a talin-dependent mechanism 6, 7 . Integrin ligation mediates thrombus formation and outside-in signalling 8, 9 , which requires Ga 13 and greatly expands thrombi. Here we show that Ga 13 and talin bind to mutually exclusive but distinct sites within the integrin b 3 cytoplasmic domain in opposing waves. The first talin-binding wave mediates inside-out signalling and also ligand-induced integrin activation, but is not required for outside-in signalling. Integrin ligation induces transient talin dissociation and Ga 13 binding to an EXE motif (in which X denotes any residue), which selectively mediates outside-in signalling and platelet spreading. The second talin-binding wave is associated with clot retraction. An EXE-motif-based inhibitor of Ga 13 -integrin interaction selectively abolishes outside-in signalling without affecting integrin ligation, and suppresses occlusive arterial thrombosis without affecting bleeding time. Thus, we have discovered a new mechanism for the directional switch of integrin signalling and, on the basis of this mechanism, designed a potent new antithrombotic drug that does not cause bleeding.
Integrin signalling involves the binding of several molecules to the cytoplasmic domain of integrin b-subunits including talin 6, 7 , kindlins 10, 11 , SRC 12, 13 and Ga 13 8 (Fig. 1a ). Co-immunoprecipitation of Ga 13 with various b 3 carboxy-terminal truncation mutants suggests that Ga 13 binding involves the b 3 sequence between Lys 729 and Thr 741 ( Fig. 1b and Extended Data Fig. 2a ), but not the kindlin-or SRC-binding sequences ( Fig. 1a, b ). Alignment of different b cytoplasmic domains reveals an EXE motif in this region, in which the first and third Glu residues are conserved among most b subunits, but not b 8 (Fig. 1a ). The EXEmotif-containing b 1 , b 2 and b 3 all bound Ga 13 , but not b 8 ( Fig. 1c and Extended Data Fig. 2f ). Wild-type and E732A mutant b 3 bound to Ga 13 , but the E731A, E733A, AAA (E731-733A) ( Fig. 1d and Extended Data Fig. 2b ), DED (E731D/E733D) and QSE (E731Q/E732S) (Extended Data Fig. 2e ) mutants did not, indicating that the first and third Glu within the EXE motif are important for Ga 13 binding. Synthetic peptides containing the EEERA sequence inhibited Ga 13 -b 3 interaction (see below), verifying this EXE-motif-containing Ga 13 -binding site.
The EXE motif is located in a talin-binding region (Fig. 1a) 14, 15 . Overexpression of the integrin-binding talin head domain (THD) in a IIb b 3 -expressing cells inhibited Ga 13 co-immunoprecipitation with b 3 (Fig. 1e ). Purified recombinant THD and Ga 13 competed directly for binding to purified glutathione S-transferase (GST)-b 3 cytoplasmic domain fusion protein (GST-b 3 CD) ( Fig. 1f, g GST-βCD and Ga 13 to b 3 . a, The sequence of the human b 3 cytoplasmic domain and its alignment with other b subunits, showing conserved EXE motifs and binding sites for talin, kindlins and SRC. b, Coimmunoprecipitation of wild-type (WT) and truncated mutant b 3 with Ga 13 and talin using antib 3 or control pre-immune (pre-im) rabbit serum. Immunoprecipitates (IP) and CHO cell lysates (10% of that used in immunoprecipitation) were immunoblotted (IB) with indicated antibodies. c, Binding of purified recombinant Ga 13 to glutathione-bead-bound GST, and cytoplasmic domain fusion proteins GST-b 1 CD, GST-b 2 CD, GST-b 3 CD or GST-b 8 CD. d, Coimmunoprecipitation of CHO-cell-expressed wildtype or EXE-motif-mutated b 3 with Ga 13 and talin using anti-b 3 or pre-immune rabbit serum. e, Coimmunoprecipitation of CHO-cell-expressed integrin a IIb b 3 with Ga 13 and THD after transfection with cDNA encoding THD. f, g, Inhibition of the binding of THD (20 nM) (f) or Ga 13 (40 nM) (g) to immobilized GST-b 3 CD proteins (wild-type and negative control mutants) by increasing concentrations of Ga 13 (f) or THD (g). Bound Ga 13 or THD was detected using anti-Ga 13 or anti-talin. Error bars represent mean 6 s.d. Fig. 2c, d ), indicating that Ga 13 and talin are mutually exclusive in binding to b 3 . Interestingly, the binding of talin and Ga 13 is regulated temporally during integrin signalling (Fig. 2 ). The first wave of talin association with a IIb b 3 occurred after thrombin-stimulated inside-out signalling ( Fig. 2a, b ) and before the onset of integrin ligation (as indicated by platelet aggregation (Fig. 2c) ). However, after integrin ligation, talin association with a IIb b 3 was diminished ( Fig. 2a, b ). The second wave of talin-b 3 association occurred after full platelet aggregation ( Fig. 2a-c) , the timing of which correlates with clot retraction. Opposite to the waves of talin binding, the Ga 13 -b 3 association was even lower than the basal level during inside-out signalling when the first talinbinding wave occurred ( Fig. 2a, b ), but peaked after integrin ligation when the first talin-binding wave subsided, and then decreased again during the second talin-binding wave ( Fig. 2a, b ). Thus, inside-out and various phases of outside-in signalling are associated with coordinated and opposing waves of Ga 13 and talin binding to b 3 . Importantly, an increase in Ga 13 binding to integrin can only be induced when integrin is activated in the presence of fibrinogen, but not by integrin activation alone (Extended Data Fig. 3a ). Conversely, the integrin inhibitors RGDS (Arg-Gly-Asp-Ser, Fig. 2a , b) or EDTA (ethylenediaminetetraacetic acid, Extended Data Fig. 3b , c) prevented dissociation of talin from b 3 and inhibited Ga 13 -b 3 interaction in thrombin-stimulated platelets. Thus, the switch from a talin-bound to a Ga 13 -bound state of a IIb b 3 is initiated by the binding of macromolecular ligands.
The opposing waves of talin and Ga 13 binding to b 3 suggest that the interaction of these two proteins with b 3 selectively mediates insideout and outside-in signalling, respectively. This hypothesis was tested using talin knockout 16 and shRNA-induced talin knockdown platelets, which are defective in adenosine diphosphate (ADP)/fibrinogen-induced, integrin-dependent aggregation (Fig. 2d , e and Extended Data Fig. 4a , c). Their defective aggregation was fully corrected with manganese or an integrin-activating antibody (LIBS6) ( Fig. 2e and Extended Data Fig. 4c ), which activate integrins independently of inside-out signalling. These data confirm a role for talin in inside-out signalling 6, 15, 17 . It is established that inside-out signalling is not the only pathway of a IIb b 3 activation. Integrin-fibrinogen interaction may occur independently of inside-out signalling when fibrinogen changes conformation, either by immobilization or conversion to fibrin 18, 19 . This is because the initial contact of the exposed ligand recognition sequence, RGD, with resting integrins triggers ligand-induced integrin activation 20 . Interestingly, adhesion of resting talin-knockout or -knockdown platelets to immobilized fibrinogen was defective ( Fig. 2f and Extended Data Fig. 4b ), indicating the importance of talin in platelet adhesion to immobilized fibrinogen in the absence of inside-out signalling. However, addition of manganese or integrin-activating antibody fully corrected talin-knockout and -knockdown platelet adhesion and spreading (and also the spreading of talin-binding-defective mutant b 3 -expressing Chinese hamster ovary (CHO) cells 21 ) on immobilized fibrinogen (Fig. 2f , g and Extended Data Fig. 4b, d , e). Thus, the role of talin in resting platelet adhesion to fibrinogen is solely due to its importance in ligand-induced integrin activation. Because cell spreading requires the early phase of outside-in signalling, these data further demonstrate that talin is not required for the early phase of outside-in signalling leading to cell spreading once its role in integrin activation is bypassed.
To assess whether Ga 13 binding to the EXE motif selectively mediates outside-in signalling without perturbing talin-dependent integrin function, wild-type and AAA mutant b 3 -transfected ITGB3 (b 3 ) 2/2 bone marrow stem cells (from b 3 2/2 mice) were transplanted into irradiated b 3 2/2 mice. The platelets from the recipient mice expressed similar levels of wild-type or AAA mutant b 3 ( Fig. 3a and Extended Data Fig. 5a ). The AAA mutation inhibited b 3 interaction with Ga 13, but not talin (or SRC) ( Fig. 3b and Extended Data Fig. 5b ), during integrin signalling. The AAA mutation also had no effect on agonistinduced soluble fibrinogen binding ( Fig. 3c ). Thus, the EXE motif is not required for talin-dependent inside-out signalling. By contrast, the AAA mutant b 3 -expressing platelets were defective in spreading on immobilized fibrinogen ( Fig. 3d and Extended Data Fig. 5c, d ). Thus, Ga 13 -binding deficiency in b 3 causes a selective defect in integrin outside-in signalling and platelet spreading. Similarly, AAA and more conserved DED or QSE b 3 mutants expressed in CHO cells, all defective in Ga 13 binding (Extended Data Fig. 2e ), and were also defective in spreading on fibrinogen (Fig. 3e , f and Extended Data Fig. 6a -c). However, AAA mutant b 3 expressed in CHO cells had no negative effect on THD binding, in contrast to the Y747A mutant (Extended Data Fig. 6d, e ). In addition, AAA-expressing cells showed defects in integrin-dependent activation of SRC (as shown by phosphorylation at Tyr 416) and transient inhibition of RHOA during cell spreading ( Fig. 3g and Extended Data Fig. 6f ), both of which are important elements of outside-in signalling. Together with previous studies that identified b 3 sequences mediating talin binding ( Fig. 1a ) 6, 15, 17, 22 , our data suggest that talin and Ga 13 dynamically interact with distinct recognition sequences in the same region of b 3 to serve as a molecular switch controlling the direction of integrin signalling.
The specific role of the EXE motif in outside-in signalling prompted us to design selective inhibitors of outside-in signalling. We synthesized several myristoylated (Myr) EXE-motif-containing b 3 peptides: mP 5 integrin signalling. a-c, Human platelets were stimulated with 0.025 U ml 21 a-thrombin (in an aggregometer) with or without 2 mM integrin inhibitor RGDS, solubilized at various time points, immunoprecipitated with anti-b 3 or pre-immune rabbit serum, and immunoblotted for Ga 13 , talin and b 3 (additional controls in Extended Data Fig. 3d ). a, Typical immunoblots. b, Quantification of immunoblots (mean 6 s.d., three experiments). OD, optical density. c, Turbidity changes indicating integrin-dependent platelet aggregation. d, Immunoblotting of talin 1 in wild-type and Tln1 2/2 (talin 1 2/2 ) mouse platelets. e, Aggregation of wild-type and talin 1 2/2 platelets stimulated with 5 mM ADP in the presence of 20 mg ml 21 fibrinogen, with or without 1 mM MnCl 2 or 0.3 mg ml 21 LIBS6. f, Adhesion of unstimulated mouse platelets to immobilized fibrinogen for 1 h, with or without 1 mM MnCl 2 or 0.18 mg ml 21 LIBS6 (quantified as percentage of loaded platelets, mean 6 s.d., n 5 4, *P , 0.001). g, Images of phalloidin-stained mouse platelets spreading on fibrinogen for 1 h, with or without 1 mM MnCl 2 or 0.18 mg ml 21 LIBS6 (quantification in Extended Data Fig. 4e ). 
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(Myr-EEERA), mP 6 (Myr-FEEERA) and mP 13 (Myr-KFEEERARAKWDT). These peptides inhibited co-immunoprecipitation between Ga 13 and b 3 (Fig. 4a and Extended Data Fig. 7a-d) , indicating that the minimal sequence of EEERA is sufficient to bind Ga 13 . By contrast, only mP 13 , but not mP 6 (or mP 5 ), inhibited talin association with b 3 (Fig. 4a) , indicating that mP 6 does not interact with talin. mP 6 inhibited platelet spreading on fibrinogen ( Fig. 4b and Extended Data Fig. 7e ), but had no effect on either agonist-induced fibrinogen/PAC1 (an ligand-mimetic antibody recognizing activated a IIb b 3 ) binding to platelets ( Fig. 4c and Extended Data Fig. 7f, g) or platelet adhesion to immobilized fibrinogen ( Fig. 4d ). Interestingly, mP 6 did not inhibit, but rather accelerated, platelet-dependent clot retraction (Fig. 4e) . These data indicate that the EXE-based inhibitor mP 6 selectively inhibits the early phase of outsidein signalling without affecting talin-dependent inside-out signalling, ligand-induced integrin activation, or the late phase of outside-in signalling associated with the second wave of talin binding. By contrast, mP 13 inhibited inside-out and outside-in signalling, as it inhibited fibrinogen binding (Extended Data Fig. 7h ), platelet adhesion ( Fig. 4d ) and clot retraction ( Fig. 4e ) (not reversed by manganese, as previously shown using talin 2/2 platelets 16 ). Thus, mP 6 selectively interferes with the early phase of outside-in signalling, but mP 13 affects all phases of integrin signalling. Importantly, mP 6 inhibited the second wave of thrombin-induced platelet aggregation in vitro (Fig. 4f ), and when injected into mice as micelles, was as potent as the currently used integrin antagonist Integrilin in inhibiting laser-induced arteriolar thrombosis ( Fig. 4g , h, Extended Data Fig. 8a, b and Supplementary Videos 1-4) and FeCl 3 -induced occlusive carotid artery thrombosis ( Fig. 4i and Extended Data Fig. 8c ). Notably, at the concentration at which both Integrilin and mP 6 similarly inhibited occlusive thrombosis, Integrilin considerably prolonged tail bleeding and increased blood loss, whereas mP 6 had no such adverse effect ( Fig. 4j and Extended Data Fig. 8d ). Thus, we have discovered a novel anti-thrombotic that prevents thrombosis without causing bleeding. Together, our study provides a conceptual advance by revealing a molecular switch controlling the directions and consequences of integrin signalling. We show that the switch between inside-out and outside-in signalling is mediated by coordinated but opposing waves of talin and Ga 13 binding to distinct yet adjacent sequences within the b 3 cytoplasmic domain. The discovery of this signalling switch forms a conceptual basis for selectively inhibiting outside-in signalling without perturbing the ligand-binding function of integrins. Importantly, we translated this new concept into a potent novel anti-thrombotic, which, unlike currently available integrin antagonists or other anti-thrombotics, potently inhibits arterial thrombosis without the adverse effect of causing bleeding (Fig. 4g-j) , a potentially life-threatening problem that limits the clinical use of current anti-integrin and anti-thrombotic therapies.
METHODS SUMMARY
Co-immunoprecipitation. Co-immunoprecipitation was performed as described previously 8 using platelets or a IIb b 3 -expressing CHO-1b9 cells 23 . Myristoylated peptide inhibitors. Myristoylated peptide inhibitors were synthesized and purified at the Research Resource Center at University of Illinois at Chicago. These include mP 5 , mP 6 and mP 13 , as well as their respective scrambled controls: mP 13 Scr (Myr-EEARERKDWAKFT), mP 5 Scr (Myr-EEARE) and mP 6 Scr (Myr-ERAFEE). The peptides were prepared in DMSO for in vitro and in micellar formulation for in vivo (and in vitro) uses. The micellar formulation has a molar ratio of PEG 2000 -DSPE, L-a-phosphatidylcholine, and peptides of 45:5:2, and was prepared as described previously 24 . mP 6 is similar to mP 6 Scr in uptake by platelets (Extended Data Fig. 9a ) and does not cause significant changes in haemogram in vivo (Extended Data Fig. 9b ). Bone marrow stem cells. Bone marrow stem cells from 6-8-week-old integrin b 3 2/2 or C57BL/6 mice were infected twice with concentrated lentivirus containing shRNA or complementary DNA constructs, then retro-orbitally injected into irradiated recipient mice (5Gy for integrin b 3 2/2 mice and 9.6Gy for C57BL/6 mice) 1 day after irradiation 8 . Platelet functional analyses 13, 25 , flow cytometry 26 , laser-induced cremaster muscle arterial thrombosis 27 and FeCl 3 -induced carotid arterial thrombosis 28 were performed as described previously. Data were analysed using t-test or one-way analysis of variance. Tail bleeding time. Analysis was performed as described previously 29 . Time to stable cessation of the bleeding is defined as no re-bleeding for 60 s. Bleeding exceeding 15 min was immediately stopped. Data were analysed using the Mann-Whitney test.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Animals and reagents. Integrin b 3
2/2 mice were obtained from the Jackson Laboratory. Tln1 fl/fl , PF4-Cre mice were provided by B. Petrich and D. Critchley 16 . Animal usage and protocol were approved by the institutional animal care committee of the University of Illinois at Chicago. For all animal experiments, mice with similar age, weight and sex ratios (1:1, except for laser-induced thrombosis) were used for control and specific treatment. The individual mice chosen for specific treatment were decided randomly. Human integrin b 3 cDNA was cloned into pcDNA3.1 vector following digestion with HindIII and Xho I, or pLenti6-V5/ Dest vector following digestion with EcoR I, Mfe I and Xho I. Truncation mutants and integrin Glu to Ala mutants were either reported previously 23 2): ITGB8-DN: 59-GCGCTCGAGTTAGAAGT TGCACCTGAAAGTTTC-39. GST-b 3 CD and recombinant Ga 13 purification was previously described 8 . Human THD cDNA, corresponding to N-terminal talin amino acid residues 1-433, was cloned into pcDNA3.1 vector and pMal-C2 vector between EcoR I and Xho I sites. Anti-RHOA antibody was purchased from Cytoskeleton; anti-Ga 13 (sc410), anti-c-Src (sc18), anti-talin (sc7534) and anti-integrin b 3 (sc6627) antibodies were from Santa Cruz Biotechnology; anti-Ga 13 (26004) was from NewEast; anti-phospho-Src Y 416 antibody was obtained from Cell Signaling; anti-talin (TA205) was from Millipore; anti-talin antibody 8d4 (T3287) was obtained from Sigma; PAC1 antibody (340507) and anti-mouse a IIb antibody MWReg3 (14-0411) were obtained from BD Biosciences; antihuman integrin b 3 antibody MAb15, LIBS6 and 8053 rabbit serum were kindly provided by M. Ginsberg (University of California, San Diego); Lipofectamine 2000, viraPower lentivirus expression system, Alexa Fluor 546-conjugated phalloidin, Alexa Fluor 488-conjugated anti-mouse secondary antibody, talin 1 shRNA plasmids (NM-011602), and non-specific shRNA control vector were from Invitrogen; Y-27632 is from Calbiochem; Fibrinogen from Enzyme Research Laboratories. Purified Ga 13 and THD binding to integrin cytoplasmic domains. GST-tagged integrin cytoplasmic domain proteins were coated onto Pierce Glutathione-coated plates overnight at 4 uC. After washing twice with NP40 buffer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1 mM NaF) with complete protease inhibitor cocktail tablets (1 tablet per 5 ml buffer, Roche), purified THD or Ga 13 proteins were added onto the plate in NP40 buffer (for Ga 13 binding, buffer contained 30 mM AlF 4 2 ). Bound THD or Ga 13 was estimated with anti-talin or anti-Ga 13 antibody, horse radish peroxide (HRP)-conjugated secondary antibody, and 3,39,5,59-tetramethylbenzidine Substrates (Pierce). The wells were washed three times with NP40 buffer between each of these steps. The reactions were terminated with 1 M sulphuric acid and measured for OD 450 nm . For the competitive inhibition assay, increasing concentrations of THD or Ga 13 was added to the reactions. Platelet preparation. Studies using human blood were approved by the institutional review board at the University of Illinois at Chicago, and informed consent was obtained from all donors. Washed human platelets from healthy donors who have not taken medication within 2 weeks before donation and platelets from 8-12-week-old mice were prepared as described previously and re-suspended in modified Tyrode's buffer 13 . Platelet aggregation assay. Platelet aggregation and secretion were measured in a turbidometric platelet aggregometer (Chronolog) at 37 uC with stirring (1,000 r.p.m.). Washed platelets (3 3 10 8 ml 21 ) in modified Tyrode's buffer were stimulated with thrombin (Enzyme Research Laboratories). Aggregation traces shown are representative of at least three independent experiments. Fibrinogen and PAC1 binding assay. For the fibrinogen binding assay, washed human or mouse platelets resuspended in modified Tyrode's buffer were incubated with 10 mg ml 21 Oregon Green-conjugated fibrinogen (Molecular Probes) and PAR4AP as described previously 23 . The reaction was diluted with PBS and analysed by flow cytometry using an Accuri C6 flow cytometry (BD Biosciences). PAC1 binding was measured with FITC-labelled PAC1 antibody (Molecular Probe).
Co-immunoprecipitation. As described previously 8 , platelets or CHO-1b9 cells expressing recombinant integrin a IIb b 3 23 were solubilized in NP40 lysis buffer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1 mM NaF), with complete protease inhibitor cocktail tablets (1 tablet per 5 ml buffer, Roche). Lysis debris was cleared after centrifugation at 14,000g for 10 min. Lysates were then immunoprecipitated with rabbit anti-Ga 13 IgG, anti-integrin b 3 rabbit serum or an equal amount of rabbit IgG or preimmune serum for 2 h before Protein A/G sepharose beads were added. After incubation of Protein A/G sepharose beads for 45 min at 4 uC, beads were centrifuged down and washed for six times with NP40 lysis buffer. Immunoprecipitates were analysed by immunoblotting. RHOA activity assay. Platelets or a IIb b 3 -expressing CHO cells in modified Tyrode's buffer or adherent on immobilized fibrinogen were solubilized in cold NP40 lysis buffer at 4uC, and debris-cleared lysates were incubated for 1 h with purified GST-RBD beads, washed, and then immunoblotted with an anti-RhoA monoclonal antibody, as described previously 8 . Bone marrow transplantation. As described previously 8 , bone marrow stem cells were isolated from femur and tibias of 6-8-week-old integrin b 3 2/2 or C57/BL6 mice using the MACS lineage cell depletion kit (Miltenyi Biotec). Stem cells were subsequently infected twice with concentrated lenti-virus containing shRNA or cDNA constructs, as described in Animals and Reagents section, using a Lenti-X concentrator (Clontech). The cells were then retro-orbitally injected into irradiated recipient mice (5Gy for integrin b 3 2/2 mice and 9.6Gy for C57/BL6 mice, one million cells per recipient mice) one day after irradiation. Platelet adhesion assay. As described previously 23 , washed platelets were preincubated with vehicle or peptides, or with either 1 mM MnCl 2 or 0.18 mg ml 21 LIBS6 before plating. After 1 h incubation at 37 uC, adherent platelets were estimated by measuring platelet phosphatase activity with 0.3% p-nitrophenyl phosphate in 1% Triton X-100, 50 mM sodium acetate, pH 5.0, for 1 h at 37 uC. The reaction was stopped with 1 M NaOH. Results were determined by reading OD 405 nm . Statistical significance was determined using t-test (n 5 3). Cell spreading, immunofluorescence and confocal microscopy. Washed platelets or a IIb b 3 -expressing CHO cells suspended in modified Tyrode's buffer were added to 100 mg ml 21 fibrinogen (Enzyme Research Laboratories)-coated cover slides and incubated at 37 uC for various lengths of time. Cells were fixed, permeabilized, blocked with 0.5% BSA in modified Tyrode's buffer, stained with mAb15 (followed by Fluor 488-conjugated anti-mouse secondary antibody) and/or Alexa Fluor 546conjugated phalloidin, and viewed with a Zeiss LSM510 META confocal microscope, as described previously 8 , or with Leica DM IRB fluorescence microscope, Photometrics CoolSNAP HQ camera and mManager software. Cell surface area was measured by NIH ImageJ analysis of 5-10 random images. Statistical significance was determined using t-test. Clot retraction assay. As previously described 8 , human PRP was incubated with vehicle or peptides for 5 min at room temperature (22 uC) before stimulation with thrombin. The two-dimensional size of retracted clots was quantified using Image J software, and statistical significance was determined using t-test (n 5 3). Peptide inhibitors. Myristoylated peptides were synthesized and purified at the Research Resource Center at the University of Illinois at Chicago. These peptides include: mP 13 (Myr-KFEEERARAKWDT), mP 5 (Myr-EEERA), mP 6 (Myr-FEEERA) and the corresponding control peptides mP 13 Scr (Myr-EEARERKDWAKFT), mP 5 Scr (Myr-EEARE), and mP 6 Scr (Myr-ERAFEE). The peptides were prepared in DMSO for use in vitro, and in micellar formulation for in vivo (and in vitro) use. For micellar formulation, PEG 2000 -DSPE, L-a-phosphatidylcholine, and peptides were mixed at a molar ratio of 45:5:2. The micelles were suspended to form micelle colloid in HEPES-saline buffer ((10 mM HEPES, 150 mM NaCl, pH 7.4), peptide concentration 1 mM) as described previously 24 . mP 6 is similar to mP 6 Scr in uptake by platelets (Extended Data Fig. 9a ) and does not cause significant changes in hemogram in vivo (Extended Data Fig. 9b ). Estimation of peptide concentration in platelets. mP 6 and mP 6 Scr peptides were dissolved and conjugated with PDAM overnight in the dark in DMSO, or conjugated in methanol and incorporated into the micelle as described above. Platelets were incubated with the PDAM-conjugated peptides for 5 min at room temperature, pelleted via centrifugation, washed and lysed with NP40 lysis buffer, and the concentration of PDAM-conjugated peptide was estimated by measuring fluorescence intensity (absorption 340 nm/emission 395 nm) as described previously 30 . Platelet lysates (without peptide incubation) were used as a blank control. Standard curve was obtained using known concentrations of peptides added to platelet lysates. In vivo FeCl 3 -induced thrombosis and tail bleeding time. 7-8-week-old C57BL/6 mice were anaesthetized by isoflurane inhalation. Retro-orbital injection of peptide micelle or integrilin (5 mmol kg 21 mouse weight) were performed 15 min before experimentation. Carotid arterial thrombosis was induced with a filter paper disc (diameter 5 2 mm) soaked with 1.2 ml of 7.5% FeCl 3 28 . Blood flow was RESEARCH LETTER monitored with a TS420 flow meter using a MA-0.5SB dopler probe (Transonic Systems). Data were analysed using one-way ANOVA. Tail bleeding time analysis were performed as described previously 29 . Time to stable cessation of bleeding was defined as no evidence of rebleeding for 60 s. Bleeding exceeding 15 min was immediately stopped by applying pressure. Statistical significance was determined using the Mann-Whitney test. Similar results were also obtained with a nonparametric ANOVA. For bleeding assays measuring total blood loss, cut mouse tails were immersed in microcentrifuge tubes with 1.5 ml of 0.15 M NaCl at 37 uC for 15 min. The haemoglobin concentration in the tube was determined using a HemoCue photometer. Data were analysed using one-way ANOVA. The experiments were performed in double-blinded fashion. Intravital microscopy and laser-induced thrombosis. Similar to the methods described previously 27 , wild-type male mice (6-8 weeks old) were anaesthetized via intraperitoneal injection of ketamine and xylazine and placed on a thermocontrolled blanket (37 uC). The cremaster muscle was exteriorized and superfused with thermo-controlled (37 uC) bicarbonate-buffered saline for the duration of experiments. Fluorescence and bright-field images were recorded using an Olympus BX61W microscope with a 603/1.0 NA water immersion objective and a highspeed camera (Hamamatsu C9300) through an intensifier (Video Scope International). Fluorescence images were captured at 20 frames per second, and data were analysed using Slidebook v5.5 (Intelligent Imaging Innovations). Arteriolar wall injury was induced with a micropoint laser ablation system (Photonics Instruments). Platelet accumulation was visualized by infusion of Dylight 649-labelled anti-mouse CD42c (Emfret, 0.05 mg g 21 body weight) into mice. Vehicle control, Integrilin, scrambled peptide or mP 6 were infused 3 min before laser injury. Laserinduced thrombi were generated at different sites in the blood vessel, with new sites upstream of earlier thrombi. Data were collected for 5 min following laser injury. The kinetics of platelet accumulation was analysed by median fluorescence values of the antibodies as a function of time in approximately 30 thrombi in three mice per group. Statistical difference of fluorescence intensity (mean 6 s.d.) at selected time points was also determined using Welch's t-test. The experiments were performed in double-blinded fashion. Statistics. For parametric data, statistical significance was analysed using Student's t-test (or Welch t-test for samples with nonequal variances) or ANOVA following determination of normal distribution and equal variances. For nonparametric data (bleeding time analysis), Mann-Whitney test was applied. Analyses were performed with GraphPad Prism 4 software. Sample size estimation was performed with Fisher's exact test using GraphPad InStat 3. 
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Extended Data Figure 3 | Ligand occupancy induces switch of integrin a IIb b 3 from the talin-bound to the Ga 13 -bound state . a, To determine the effect of integrin activation and ligand occupancy on Ga 13 -b 3 association, human platelets were incubated with or without 1 mM MnCl 2 and 30 mg ml 21 fibrinogen for 5 min at 22 uC. Platelet lysates were then immunoprecipitated with anti-b 3 or pre-immune rabbit serum. Lysates (10%) and immunoprecipitates were immunoblotted with anti-b 3 or anti-Ga 13 . b, c, Washed human platelets were stimulated with 0.025 U ml 21 a-thrombin with or without adding 2 mM EDTA (an inhibitor of the ligand binding function of integrins), stirred (1,000 r.p.m.) at 37 uC, solubilized at various time points, and immunoprecipitated with anti-b 3 or equal amounts of pre-immune rabbit serum. Lysates (10%) and immunoprecipitates were immunoblotted with anti-Ga 13 , anti-talin or anti-b 3 antibodies. b, Western blot results. c, Turbidity changes in platelet suspension indicating integrin-dependent platelet aggregation. Note the inhibitory effect of EDTA on talin dissociation and Ga 13 binding to b 3 . d, As additional controls for Fig. 2a to exclude the possibility of loss of talin and b 3 in platelet lysates to insoluble fraction during integrin signalling, washed human platelets were stimulated with 0.025 U ml 21 a-thrombin in the absence or presence of 2 mM integrin inhibitor RGDS, stirred (1,000 r.p.m.) at 37 uC, and then solubilized at various time points as in Fig. 2a . Solubilized platelets were centrifuged at 14,000g for 10 min to separate lysates from insoluble pellets. Pellets were dissolved in SDS sample buffer to the same volume as the lysates after diluting them 1:1 with 23 SDS sample buffer, and both were immunoblotted with anti-b 3 and anti-talin antibodies. Note that the levels of talin and b 3 in platelet lysates kept essentially constant during the course of platelet aggregation and, with low concentrations of thrombin used to stimulate platelets, very little insoluble b 3 and talin were present in the pellet, which were detectable only after prolonged exposure (5-min exposure compared to 10 s of normal exposure time) and with no obvious variation during the course of platelet aggregation.
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Extended Data Figure 4 | Effects of shRNA-induced talin knockdown and talin knockout on integrin signalling. a, Western blot comparison of talin 1 expression levels in mouse platelets derived from control shRNA-or talin-shRNA-transfected bone marrow stem cells. Western blots of Ga 13 , and integrin b 1 and b 3 are also shown. b, Adhesion of unstimulated mouse platelets to immobilized fibrinogen for 1 h. Adherent platelets were quantified as percentage of total platelets loaded (mean 6 s.d., n 5 4). c, Turbidity changes in mouse platelet suspension stimulated with 5 mM ADP in the presence of 20 mg ml 21 fibrinogen, with or without 1 mM MnCl 2 , as detected using an aggregometer. d, Fluorescence microscopy images of phalloidin-stained mouse platelet spreading on fibrinogen for 1 h, with or without 1 mM MnCl 2 . e, Quantification of surface areas of individual adherent platelets as shown in Fig. 2g (mean 6 s.e.m.).
LETTER RESEARCH
